Summary
Alfa Wassermann S.p.A. (Alfa Wassermann) is a pharmaceutical company that research, produces and distributes drugs for human health. The company offers new discoveries in medicine, biology and genomics. It provides self-medication products for treatment of sore throat, headaches, and muscle and joint pain. The company also offers antibiotics used for treatment of diseases such as vascular diseases, deep venous thrombosis and gastrointestinal tract diseases. It operates through its subsidiaries located in the US, the Netherlands, Mexico, France, Spain, Portugal, China, Poland, Romania, Tunisia and Slovakia. Alfa Wassermann is headquartered in Bologna, Italy.
Alfa Wassermann S.p.A - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Alfa Wassermann S.p.A, Medical Devices Deals, 2010 to YTD 2016 10
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Alfa Wassermann to Acquire Italian Operations from Sigma-Tau 13
Sigma-Tau Acquires Specialty Pharma Business From Enzon Pharma 14
Partnerships 16
Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 16
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 18
Theravance Enters Into Co-Development Agreement With Alfa Wassermann For Velusetrag 19
a V.I. Pharma Enters into Distribution Agreement with Sigma-Tau for Eurartesim 21
Norgine Enters Into Co-Marketing Agreement With Alfa Wassermann 22
Licensing Agreements 24
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 24
Sigma-Tau Pharma Enters into Licensing Agreement with Crosscare for Colief 25
Soligenix Terminates Licensing Agreement With Sigma-Tau Pharma For orBec 26
Soligenix Expands Licensing Agreement With Sigma-Tau Pharma For orBec 27
ASKA Pharma Enters into Licensing Agreement with Alfa Wassermann 29
Gentium Enters Into Licensing Agreement With Sigma-Tau Pharma 30
Equity Offering 32
RegeneRx BioPharma Completes Registered Direct Offering Of US$1.45 Million 32
Soligenix Completes Private Placement Of Its Common Stock For US$6 Million 34
Asset Transactions 36
Alfa Wassermann to Acquire Italian Operations from Sigma-Tau 36
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 37
Acquisition 39
Sigma-Tau May Sell Sigma-Tau Pharma 39
Alfa Wassermann Acquires Promefarm 40
Alfa Wassermann S.p.A - Key Competitors 41
Key Employees 42
Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45
List of Tables
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Key Facts 1
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Alfa Wassermann S.p.A, Deals By Therapy Area, 2010 to YTD 2016 8
Alfa Wassermann S.p.A, Medical Devices Deals, 2010 to YTD 2016 10
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Alfa Wassermann to Acquire Italian Operations from Sigma-Tau 13
Sigma-Tau Acquires Specialty Pharma Business From Enzon Pharma 14
Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 16
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 18
Theravance Enters Into Co-Development Agreement With Alfa Wassermann For Velusetrag 19
a V.I. Pharma Enters into Distribution Agreement with Sigma-Tau for Eurartesim 21
Norgine Enters Into Co-Marketing Agreement With Alfa Wassermann 22
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 24
Sigma-Tau Pharma Enters into Licensing Agreement with Crosscare for Colief 25
Soligenix Terminates Licensing Agreement With Sigma-Tau Pharma For orBec 26
Soligenix Expands Licensing Agreement With Sigma-Tau Pharma For orBec 27
ASKA Pharma Enters into Licensing Agreement with Alfa Wassermann 29
Gentium Enters Into Licensing Agreement With Sigma-Tau Pharma 30
RegeneRx BioPharma Completes Registered Direct Offering Of US$1.45 Million 32
Soligenix Completes Private Placement Of Its Common Stock For US$6 Million 34
Alfa Wassermann to Acquire Italian Operations from Sigma-Tau 36
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 37
Sigma-Tau May Sell Sigma-Tau Pharma 39
Alfa Wassermann Acquires Promefarm 40
Alfa Wassermann S.p.A, Key Competitors 41
Alfa Wassermann S.p.A, Key Employees 42
Alfa Wassermann S.p.A, Other Locations 43
Alfa Wassermann S.p.A, Subsidiaries 43
List of Figures
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Alfa Wassermann S.p.A, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Alfa Wassermann S.p.A, Medical Devices Deals, 2010 to YTD 2016 10
